Apolipoprotein polymorphisms and familial hypercholesterolemia

Pharmacogenomics

Volumn 8, Issue 9, 2007, Pages 1179-1189

  Dedoussis, George V Z ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Apolipoproteins; Cluster; Familial hypercolesterolemia; Low density lipoprotein receptor; Polymorphism

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN A5; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEIN M; CHYLOMICRON; GUANINE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SCAVENGER RECEPTOR BI; THYMIDINE; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

CALORIC RESTRICTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; ENZYME ACTIVATION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PREVALENCE; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; XANTHOMA;

APOLIPOPROTEINS; CHOLESTEROL, HDL; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; POLYMORPHISM, GENETIC; RECEPTORS, LDL;

EID: 35348908391     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.9.1179     Document Type: Review

References (89)

1. Goldstein JL, Hobbs HH, Brown MS: Familial hypercholesterelomia. In: The Metabolic and Molecular Basis of Inherited Disease. Scriver CR, Beaudet AL, Sly WS et al. (Eds). McGraw-Hill, NY, USA, 1981-2029 (1995).
2. Tybjaerg-Hansen A. Humphries SE: Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease. Atheroclerosis 96, 91-107 (1992).
3. Abifadel M, Varret M, Rabes JP et al.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156 (2003).
4. Dedoussis GV, Skoumas J, Pitsavos C et al.: FH-clinical phenotype in Greek patients with LDL-R defective vs. negative mutations. Eur J. Clin. Invest. 34, 402-409 (2004).
5. Bertolini S, Cantafora A, Averna M et al.: Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler. Thromb. Vasc. Biol. 20, E41-E52 (2000).
6. Pisciotta L, Priore Oliva C, Pes GM et al.: Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison. Atherosclerosis 188, 398-405 (2006).
7. Goldstein JL, Brown MS: The LDL receptor defect in familial hypercholesterolemia. Med. Clin. North Am. 66, 335-362 (1982).
8. Austin MA, Hutter CM, Zimmern RL, Humphries SE: Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am. J. Epidemiol. 160, 421-429 (2004).
9. Jansen AC, van Aalst-Cohen ES, Tanck MW et al.: The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J. Intern. Med. 256, 482-490 (2004).
10. Dedoussis GV, Schmidt H, Genschel J: LDL-receptor mutations in Europe. Hum. Mutat. 24, 443-459 (2004).
11. Bertolini S, Pisciotta L, di Scala L et al.: Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia. Atheroclerosis 174, 57-65 (2004).
12. Ferrieres J, Lambert J, Lussier-Cacan S, Davignon J: Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 92, 290-295 (1995).
13. Pimstone SN, Sun XM, du Souich C et al.: Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. Arterioscler. Thromb. Vasc. Biol. 18, 309-315 (1998).
14. Sorci-Thomas M, Prack MM, Dashti N et al.: Differential effects of dietary fat on the tissue-specific expression of the apolipoprotein A-I gene: relationship to plasma concentration of high density lipoproteins. J. Lipid. Res. 30, 1397-1403 (1989).
15. Wang CS, McConathy WJ, Kloer, HU, Alaupovic P: Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J. Clin. Invest. 75, 384-390 (1985).
16. Ebara T, Ramakrishnan R, Steiner G, Shachter NS: Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J. Clin. Invest. 99, 2672-2681 (1997).
17. Groenendijk M, Cantor RM, de Bruin TW, Dallinga-Thie GM: The apoAI-CIII-AIV gene cluster. Atherosclerosis 157, 1-11 (2001).
18. Beisiegel U, Utermann G: An apolipoprotein homolog of rat apolipoprotein A-IV in human plasma. Isolation and partial characterisation. Eur. J. Biochem. 93, 601-608 (1979).
19. Xu N, Dahlback B: A novel human apolipoprotein (apoM). J. Biol. Chem. 274, 31286-31290 (1999).
20. Faber K, Axler O, Dahlback B, Nielsen LB: Characterization of apoM in normal and genetically modified mice. J. Lipid. Res. 45, 1272-1278 (2004).
21. Wolfrum C, Poy MN, Stoffel M: Apolipoprotein M is required for preβ-HDL formation and cholesterol efflux to HDL and protects against Atherosclerosis Nat. Med. 11, 418-422 (2005).
22. Jakel H, Nowak M, Helleboid-Chapman A, Fruchart-Najib J, Fruchart JC: Is apolipoprotein A5 a novel regulator of trilyceride-rich lipoproteins? Ann. Med. 38, 2-10 (2006).
23. Pennacchio, LA, Olivier M, Hubacek JA et al.: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294, 169-173 (2001).
24. van der Vliet HN, Sammels MG, Leegwater AC et al.: Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J. Biol. Chem., 276. 44512-44520 (2001).
25. Williamson R, Lee D, Hagaman J. Maeda N. Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc. Natl Acad. Sci. USA 89, 7134-7138 (1992).
26. Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB Jr: Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis 2, 16-26 (1982).
27. Moore RE, Navab M. Millar JS et al.: Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ. Res. 97, 763-771 (2005).
28. Wang X, Palgen B: Genetics of variation in HDL cholesterol in humans and mice. Circ. Res. 96, 27-42 (2005).
29. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL: Hypertiglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 249, 790-793 (1990).
30. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J: Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biol. Chem. 269, 23610-23616 (1994).
31. Miller M, Zhan M: Genetic determinants of low high-density lipoprotein cholesterol. Curr. Opin. Cardiol. 19, 380-384 (2004).
32. Pallaud. C, Gueguen R. Sass C et al.: Genetic influences on lipid metabolism trait variability within the Stanislas cohort. J. Lipid. Res. 42, 1879-1890 (2001).
33. Ordovas JM, Corella D. Cupples LA et al.: Polyunsaturated fatty acids modulate the effects of the APOA1 G-A polymorphism on HDL-cholesterol concentrations in a sex-speciftc manner: the Framingham Study. Am. J. Clin. Nutr. 75, 38-46 (2002).
34. Brown S, Ordovas JM. Campos H: Interaction between the APOC3 gene promoter polymorphisms, saturated fat intake and plasma lipoproteins. Atherosclerosis 170, 307-313 (2003).
35. Brown CM, Rea TJ. Hamon SC et al.: The contribution of individual and pairwise combinations of SNPs in the APOA1 and APOC3 genes to interindividual HDL-C variability. J. Mol. Med. 84. 561-572 (2006).
36. Li GP, Wang JY. Yan SK, Chen BS, Xue H, Wu G: Genetic effect of two polymorphisms in the apolipoprotein A5 gene and apolipoprotein C3 gene on serum lipids and lipoproteins levels in a Chinese population. Clin. Genet. 65, 470-476 (2004).
37. Lai CQ. Tai ES, Tan CE et al.: The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J. Lipid. Res. 44, 2365-2373 (2003).
38. Lai CQ, Demissie S, Cupples LA et al.: Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study J Lipid. Res. 45, 2096-2105 (2004).
39. Talmud PJ, Martin S, Taskinen MR et al.: APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. J. Lipid. Res. 45, 750-756 (2004).
40. Eichenbaum-Voline S, Olivier M, Jones EL et al.: Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 24, 167-174 (2004).
41. Pennacchio LA, Olivier M, Hubacek JA, Krauss RM. Rubin EM, Cohen JC: Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum. Mol. Genet. 11, 3031-3038 (2002).
42. Priore Oliva C, Pisciotta L, Li Volti G et al.: Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 25, 411-417 (2005).
43. Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622-630 (1988).
44. Sing CF, Davignon J: Role of the apolipoprotein E polymorphism in determining normal plasm lipid and lipoprotein variation. Am. J. Hum. Genet. 37, 268-285 (1985).
45. Ehnholm C, Lukka M, Kuusi T, Nikkila E, Utermann G: Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J. Lipid. Res. 27, 227-235 (1986).
46. Davignon J, Gregg RE. Sing CF: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8, 1-21 (1988).
47. Xhignesse M, Lussier-Cacan S, Sing CF, Kessling AM, Davignon J: Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. Arterioscler. Thromb. 11, 1100-1110 (1991).
48. Lehtimaki T, Moilanen T, Viikari J et al.: Apolipoprotein E phenotypes in Finnish youths: a cross-sectional and 6-year follow-up study. J. Lipid. Res. 31, 487-495 (1990).
49. Gronroos P. Raitakari OT, Kahonen M et al.: Influence of apolipoprotein E polymorphism on serum lipid and lipoprotein changes: a 21-year follow-up study from childhood to adulthood. The Cardiovascular Risk in Young Finns Study. Clin. Chem. Lab. Med. 45, 592-598 (2007).
50. Vilri LE, Loimaala A, Nenonen A et al.: The association of the apolipoprotein E gene promoter polymorphisms and haplotypes with serum lipid and lipoprotein concentrations. Atherosclerosis 179, 161-167 (2005).
51. Viiri LE. Raitakari OT, Huhtala H et al.: Relations of APOE promoter polymorphisms to LDL cholesterol and markers of subclinical atherosclerosis in young adults. J. lipid. Res. 47, 1298-1306 (2006).
52. Song Y, Stampfer MJ, Liu S: Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann. Intern. Med. 141, 137-147 (2004).
53. Saito M, Eto M, Nitta H et al.: Effect of apolipoprotein E4 allelé on plasma LDL cholesterol response to diet therapy in type 2 diabetic patients. Diabetes Care. 27, 1276-1280 (2004).
54. Lohse P, Kindt MR, Rader DJ, Brewer HB Jr: Genetic polymorphism of human plasma apolipoprotein A-IV is due to nucleotide substitutions in the apolipoprotein A-IV gene. J. Biol. Chem. 265, 10061-10064 (1990).
55. McCombs RJ. Marcadis DE, Ellis J. Weinberg RB: Attenuated hypercholesterolemic response to a high-cholesterol diet in subjects heterozygous for the apolipoprotein A-IV-2 allele. N. Engl. J. Med. 331, 706-710 (1994).
56. Campos H, Lopez-Miranda, J, Rodriguez C, Albajar M, Schaefer EJ, Ordovas JM: Urbanization elicits a more atherogenic lipoprotein profile in carriers of the apolipoprotein A-IV-2 allele than in A-IV-1 homozygotes. Arterioscler. Thromb. Vasc. Biol. 17, 1074-1081 (1997).
57. Boekholdt SM, Peters RJ, Fountoulaki K, Kastelein JJ. Sijbrands EJ: Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis. Hum. Genet. 113, 417-425 (2003).
58. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk. 3, 213-219 (1996).
59. Stampfer MJ, Krauss RM, Ma J et al.: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276, 882-888 (1996).
60. Miller M: Is hypertriglyceridaemia an independent risk factor for coronary heart disease? The epidemiological evidence. Eur Heart. J. 19(Suppl. H), H18-H22 (1998).
61. Kao JT, Wen HC, Chien KL, Hsu HC, Lin SW: A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum. Mol. Genet. 12, 2533-2539 (2003).
62. Baroukh N, Bauge E, Akiyama J et al.: Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler. Thromb. Vasc. Biol. 24, 1297-1302 (2004).
63. Brunzell JD, Albers JJ, Chait A, Grundy SM,Groszek E, McDonald GB: Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J. Lipid. Res. 24, 147-155 (1983).
64. Talmud, PJ, Hawe E, Martin S et al.: Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum. Mol. Genet. 11, 3039-3046 (2002).
65. Liu H, Zhang S, Lin J et al.: Association between DNA variant sites in the apolipoprotein A5 gene and coronary heart disease in Chinese. Metabolism 54, 568-572 (2005).
66. Bi N, Yan SK, GP Li, Yin ZN, Chen BS: A single nucleotide polymorphism -1131T>C in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and alters triglyceride metabolism in Chinese. Mol. Genet. Metab. 83, 280-286 (2004).
67. Szalai C, Kesmi M, Duba J et al.: Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with-an increased susceptibility for coronary artery disease. Atherosclerosis 173, 109-114 (2004).
68. Hokanson JE, Krauss RM, Albers JJ. Austin MA, Brunzell JD: LDL physical and chemical properties in familial combined hyperlipidemia. Arterioscler: Thromb. Vasc. Biol. 15, 452-429 (1995).
69. Walldius G, Jungner I: Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur. Heart J. 26, 210-212 (2005).
70. Yusuf S, Hawken S, Ounpuu S et al.: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364, 937-952 (2004).
71. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358, 2026-2033 (2001).
72. Sposito AC, Gonbert S, Turpin G, Chapman MJ, Thinet J: Common promoter C516T polymorphism in the ApoB gene is an independent predictor of carotid atherosclerotic disease in subjects presenting a broad range of plasma cholesterol levels. Arterioscler: Thromb. Vasc. Biol. 24, 2192-2195 (2004).
73. van't Hooft FM, Jormsjo S. Lundahl B, Tornvall P, Eriksson P, Hamsten A: A functional polymorphism in the apolipoprotein B promoter that influences the level of plasma low density lipoprotein. J. Lipid. Res. 40, 1686-1694 (1999).
74. Ilveskoski E, Perola M, Lehtimaki T et al.: Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: an autopsy study. Circulation 100, 608-613 (1999).
75. Nieminen T, Kähonen M, Lehtimaki T: The.effects of apoA-II-III/ A-IV, apoE and apoB polymorphisms on carotid artery intima-media thickness. Future Cardiol. 2(2), 179-186 (2006).
76. Eto M, Watanabe K, Chonan N, Ishii K: Familial hypercholesterolemia and apolipoprotein E4. Atherosclerosis 72, 123-128 (1988).
77. Humphries SE, Talmud PJ, Hawe E, Bolla M, Day IN, Miller GJ: Apolipoprotein E4 and cor onary heart disease in middle-aged men who smoke: a prospective study. Lancet 358, 115-119 (2001).
78. Christidis DS, Liberopoulos EN, Kakafika Al et al.: The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J. Cardiovasc. Pharmacol. Ther. 11, 211-221 (2006).
79. Pitsavos C, Choumerianou DM, Skoumas J et al.: Apolipoprotein E polymorphism is not associated with lipid levels and coronary artery disease in Greek patients with familial hypercholesterolaemia. Clin. Exp. Med. 5, 196-201 (2005).
80. Vuorio AF, Turtola H, Pillahti KM, Repo P, Kanninen T, Kontula K: Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study. Arterioscler. Thromb. Vasc. Biol. 17, 3127-3138 (1997).
81. Vohl MC, Szots F, Lelievre M et al.: Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Atherosclerosis 160, 361-368 (2002).
82. Real JT, Chaves FJ, Martinez-Uso I, Garcia-Garcia AB, Ascaso JF, Carmena R: Importance of HDL cholesterol levels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia. Eur. Heart J. 22, 465-471 (2001).
83. Tato F, Keller C, Schuster H, Spengel F, Wolfram G, Zollner N: Relation of lipoprotein(a) to coronary heart disease and duplexsonographic findings of the carotid arteries in heterozygous familial hypercholesterolemia. Atherosclerosis 101, 69-77 (1993).
84. van Aalst-Cohen ES, Jansen AC, Boekholdt SM et al.: Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia. Eur. J. Hum. Genet. 13, 1137-1142 (2005).
85. Dedoussis GV, Maumus S, Chournerianou DM et al: Different genes and polymorphisms affecting high-density lipoprotein cholesterol levels in greek familial hypercholesterolemia patients. Genet. Test 10, 192-199 (2006).
86. Blangero J, Williams JT, Almasy L: Quantitative trait locus mapping using human pedigrees. Hum. Biol. 72, 35-62 (2000).
87. Mackay TF: The genetic architecture of quantitative traits. Annu. Rev. Genet. 35, 303-339 (2001).
88. Nelson MR, Kardia SL, Ferrell RE, Sing CF: A combinatorial partitioning method to identify multilocus genotypic partitions that predict quantitative trait variation. Genome Res. 11, 498-470 (2001).
89. Hamon SC, Kardia SL, Boerwinkle E et al.: Evidence for consistent intragenic and intergenic interactions between SNP effects in the APOA1/C3/A4/A5 gene cluster. Hum. Hered. 61, 87-96 (2006).